Form 4: Akebia Therapeutics CMO Granted Significant Equity Awards

Akebia Therapeutics' SVP and Chief Medical Officer, Steven Keith Burke, was granted 204,000 restricted stock units and 320,000 stock options.

Summary

• Steven Keith Burke, SVP, Chief Medical Officer of Akebia Therapeutics, Inc. (AKBA), was granted 204,000 restricted stock units (RSUs) and 320,000 stock options on January 30, 2026.
• The RSUs were granted at a price of $0.00 and will vest one-third on each of the first, second, and third anniversaries of the grant date, subject to continued service.
• The stock options have an exercise price of $1.41 and will vest 25% on the first anniversary of the grant date, with the remaining 75% vesting in equal quarterly installments thereafter, subject to continued service.
• Both the RSUs and stock options were granted pursuant to the Issuer's 2023 Stock Incentive Plan, as amended.
• Following these transactions, Mr. Burke beneficially owns 1,016,090 shares of common stock and 320,000 stock options.
• The common stock beneficial ownership includes 1,500 shares purchased on June 30, 2025, and 1,500 shares purchased on December 31, 2025, under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development for executive retention and alignment of interests, though it represents routine compensation and does not indicate a significant change in the company's operational or financial outlook.

Positives

• The equity grants align the interests of a key executive, Steven Keith Burke, with those of shareholders, incentivizing long-term performance.
• The vesting schedules for both RSUs and stock options promote executive retention over several years.

Negatives

• The grants represent potential future dilution for existing shareholders upon vesting and exercise of the awards.
• There is no immediate cash benefit to the company from these grants, as they are non-cash compensation.

Risks

• The value of the equity awards is subject to the future performance of Akebia Therapeutics' stock price, which could decline.
• The reporting person's continued service is a condition for vesting, meaning the awards could be forfeited if employment ceases before vesting dates.

Future Outlook

The equity grants are designed to serve as a long-term incentive for the Chief Medical Officer, aligning his future performance with the company's success and shareholder value creation over the next several years through vesting schedules.

Industry Context

StockSavvy.ai notes that equity-based compensation, such as restricted stock units and stock options, is a standard and widely adopted practice in the biotechnology and pharmaceutical industries. This approach is crucial for attracting, retaining, and motivating key scientific and executive talent, particularly in companies like Akebia Therapeutics, where long-term drug development cycles necessitate sustained commitment and performance from leadership.

Comparison to Industry Standards

• Equity grants of this nature and size for a Senior Vice President and Chief Medical Officer are consistent with compensation practices observed across comparable biotech companies, reflecting the importance of retaining experienced leadership in drug development.
• The vesting schedules (three years for RSUs, four years for options) are typical for executive long-term incentive plans in the industry, aiming to ensure sustained commitment.

Stakeholder Impact

• Shareholders: Potential for minor dilution from future share issuance upon vesting and exercise of awards, but also benefit from aligned management incentives.
• Employees: The grants to a key executive may signal stability and a commitment to long-term growth within the company.

Next Steps

• Vesting of 204,000 restricted stock units on the first, second, and third anniversaries of January 30, 2026.
• Vesting of 320,000 stock options, with 25% vesting on the first anniversary of January 30, 2026, and the remainder in equal quarterly installments thereafter.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation for a key executive and does not provide new information that would significantly alter the investment thesis for Akebia Therapeutics. It reinforces management's long-term commitment but doesn't warrant a change in rating based solely on this filing.

Keywords

Akebia Therapeutics, AKBA, Steven Keith Burke, Form 4, SEC filing, stock options, restricted stock units, equity compensation, executive compensation, insider transaction